

Press Release

Astellas Announces Personnel Changes and Organizational Changes

Tokyo, February 5, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka) today announced the personnel changes and organizational changes as below.

1. Appointments of Senior Corporate Executive effective April 1, 2018

Name	New Title	Current Title
Chihiro Yokota	CEO's Office	Head of Japan-Asia Development, Development
Wataru Uchida	CEO's Office	Head of Drug Discovery Research
Makoto Takeuchi	CEO's Office	Senior Vice President, External Relations

CEO: Chief Executive Officer

2. Appointments of Corporate Executive effective April 1, 2018

Name	New Title	Current Title
Kazunori Okimura	CEO's Office	Corporate Vice President, Legal
Katsumi Ozawa	CEO's Office	General Manager, Tokyo Branch, Japan Sales & Marketing
Chikashi Takeda	CFO and Head of Finance	CFO
Fumiaki Sakurai	CAO & CECO and Head of Human Resources	CAO & CECO
Naoki Okamura	CSTO	Corporate Vice President, Corporate Planning
Akihiko Iwai	Head of Drug Discovery Research	Divisional Senior Vice President, Candidate Discovery Science Labs., Drug Discovery Research
Shigeki Tanaka	Head of Japan-Asia Development, Development	Vice President, Japan-Asia Clinical Development 1, Development
Atsushi Kamide	Vice President, External Relations	Vice President, Healthcare Policy & CSR

CFO: Chief Finance Officer

CAO: Chief Administrative Officer

CECO: Chief Ethics & Compliance Officer

CSTO: Chief Strategy Officer

3. Resignation of Senior Corporate Executive effective June 15, 2018

Name	Title (effective on April 1, 2018)
Chihiro Yokota	CEO's Office
Wataru Uchida	CEO's Office
Makoto Takeuchi	CEO's Office

4. Resignation of Corporate Executive effective June 15, 2018

Name	Title (effective on April 1, 2018)
Kazunori Okimura	CEO's Office
Katsumi Ozawa	CEO's Office

5. Appointment of Senior Corporate Executive effective June 15, 2018

Name	Title (effective on April 1, 2018)
Chikashi Takeda	CFO and Head of Finance
Nobuaki Tanaka	Head of Japan Sales & Marketing
Akihiko Iwai	Head of Drug Discovery Research
Atsushi Kamide	Senior Vice President, External Relations

6. New Corporate Executives effective June 15, 2018

Name	Title (effective on April 1, 2018)
Shiro Yamamoto	General Manager, Tokyo Branch, Japan Sales & Marketing
Masaaki Hirano	Corporate Vice President, Corporate Planning
Yoshitsugu Shitaka	President, Astellas Institute for Regenerative Medicine

7. Personnel Changes effective April 1, 2018

Name	New Title	Current Title
Kazuhiko Kawasaki	Head of Internal Auditing and Vice President, Internal Auditing	Vice President, Internal Auditing
Masaaki Hirano	Corporate Vice President, Corporate Planning	Divisional Senior Vice President, Modality Research Labs., DDR
Yuta Watanabe	Vice President, Rx+ Business Accelerator	Vice President, Japan-Asia Planning & Administration, Medical & Development
Osamu Chihara	Vice President, Healthcare Policy & CSR	Senior Director, Healthcare Policy & CSR
Stig Ogata	Vice President, Corporate Communications	Senior Director, Business Strategy & Operations, Marketing Strategy Astellas Pharma US, Inc.

Satoshi Nozaki	Vice President, Legal	Staff Executive Director, Legal
Minori Saitoh	Vice President, Research Planning & Administration, DDR	Vice President, Drug Repurposing and Application Management, DDR
Taro Masunaga	Vice President, Research Portfolio Planning, DDR	Executive Director, Innovation & Incubation Research Labs., DDR
Tatsuaki Morokata	Divisional Senior Vice President, Innovation & Incubation Research Labs., DDR	Executive Director, Product & Portfolio Strategy
Yuichi Tomura	Divisional Senior Vice President, Candidate Discovery Science Labs., DDR	Vice President, Research Portfolio Planning, DDR
Shigeki Kawabata	Vice President, New Medical Solutions, DDR	Vice President, Evolving Medical Solutions, DDR
Noriyuki Masuda	Divisional Senior Vice President, Modality Research Labs., DDR	Vice President, Research Planning & Administration, DDR
Shigeru Nakaji	Vice President, Japan-Asia Planning & Administration, Medical & Development	Executive Director, Japan-Asia Clinical Development 1, Development
Hiroaki Ishikura	Vice President, Japan-Asia Clinical Development 1, Development	Senior Director, Japan-Asia Clinical Development 1, Development
Kei Motonaga	Vice President, Analytical Research Laboratories, Pharmaceutical Technology	Senior Director, Quality Control Division, Yaizu Technology Center
Koji Nagao	Vice President, Pharmaceutical Science & Technology Labs., Pharmaceutical Technology	Pharmaceutical Technology
Masaaki Usui	Divisional Senior Vice President, Product Marketing, Japan Sales & Marketing	Vice President, Corporate Communications
Shiro Yamamoto	General Manager, Tokyo Branch, Japan Sales & Marketing	Divisional Senior Vice President, Product Marketing, Japan Sales & Marketing
Takashi Matsuki	Vice President, Business Planning, Asia & Oceania Business	President, P.T. Astellas Pharma Indonesia

DDR: Drug Discovery Research

[Staff Executive Director]

Name	New Title	Current Title
Masahiro Takeuchi	Staff Executive Director, DDR	Executive Director, Candidate Discovery Science Labs., DDR
Tomoyuki Yasunaga	Staff Executive Director, Planning & Administration, DDR	Executive Director, Planning & Administration, DDR
Hideto Yamaguchi	Staff Executive Director, Pharmaceutical Technologies	Senior Director, Pharmaceutical Technologies

8. Organizational Changes effective April 1, 2018

Establishment of Rx+ Business Accelerator

To create new business models for Rx+ (innovative medical solutions by combining a variety of internal and external capabilities) and build business case capability, implement idea-seeking collaborations and create processes to manage Rx+ projects, a special team within Corporate Planning will be reorganized into the Rx+ Business Accelerator.

Changes to Drug Discovery Research

To ensure reliability and increase the efficiency of research program management, the application management function of Drug Repurposing will be transferred to Research Program Management. The drug repurposing research function of Drug Repurposing will be transferred to EMed, and Drug Repurposing will be effectively dissolved. EMed will be transferred to New Medical Solutions, and serve as a research function, including drug repurposing research of new medical solutions.

Establishment of Pharmaceutical Science & Technology Labs

To shorten the time from discovery to Proof-of-Concept (POC), a part of functions / staff at the current four Labs (Process Chemistry Labs, Biotechnology Labs, Pharmaceutical Research & Technology Labs and Analytical Science Labs) in Pharmaceutical Technologies will be transferred / integrated into Pharmaceutical Science & Technology Labs (PSTL). The PSTL will have flexibility to respond to every modality within the five Labs. structure of Pharmaceutical Technologies.

###

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473